Edgewise Therapeutics, Inc.
Extract: Charter Amendment (Plain English Desc) (Inactive) from a 8-K on 06/11/2024   Download
SEC Document
SEC Filing

On June 10, 2024, following the vote on proposal 3 at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Edgewise Therapeutics, Inc. (the “Company”), the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation, which amendment was effective upon filing. Specifically, the Certificate of Amendment amended Section 1 of Article IX in its entirety to read as follows:

“Section 1. To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended from time to time, a director or officer of the Company shall not be personally liable to the Company or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Company shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.”